Determination of High-Sensitivity C-reactive protein in Patient with Early Parkinson's disease

Parkinson's disease (PD) is a common neurodegenerative disorder. The pathogenesis of PD is unknown till now. The high-sensitivity C-reactive protein (CRP) is a non-specific biochemical marker of inflammation. It is used for the screening of organ diseases and the monitoring of responses to treatment in cases of inflammation and infection. This study aimed to evaluate the relationship of high-sensitivity C-reactive protein in early Parkinson disease. A total of seventy-six early Parkinson's disease patients were enrolled in this Cross-sectional observational study which was carried out in the Department of Neurology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh from September 2014 to March 2016. We assessed high sensitivity CRP of early Parkinson's disease patients as an inflammatory marker. This study was performed with 76 early Parkinson disease patients. Among them, male and female were 69.7% and 30.3% respectively. The mean ±SD age of patients was 53.25±11.53 years with an age range of 24 to 77 years. The mean ±SD value of high-sensitivity C-reactive protein was estimated 2.76±3.57 mg/L with the range of 0.21 to 20.90mg/L. We also calculate the 95% CI in the range of 1.96 to 3.56mg/L. Also, a positive and highly significant correlation were seen in between duration of tremor and High sensitivity CRP (r=0.430, p<0.001) and between duration of bradykinesia and High sensitivity CRP (r=0.426, p<0.001) which indicate increase duration causes increase level of high-sensitivity C-reactive protein value. In conclusion, above findings suggests that neuro-inflammation plays a significant role in the pathogenesis of early Parkinson's disease progression.